Sunday Science: Testosterone Therapy – Risks, Benefits & Longevity Debate

Summary by Speaker

Dr. Brent Laartz

Discusses testosterone decline with age (0.4-2.6%/year, 30-50% by 50-60), low T (

Reviews studies: - Low T associated with 1.5-2.3x higher all-cause, CV, cancer mortality (2010 European Heart Journal cohort; 2011 JCEM meta-analysis). - Frailty mediates 35% of low T mortality risk. - Eunuch/castration studies (Korea, Poland, animals): 10-20% longer lifespan, but pre-puberty vs. late-life low T. - TRT studies: Decreased mortality if levels normalized (2012, 2015 European Heart Journal cohorts); short-term (3 years) benefit; non-normalized TRT no benefit.

Notes biases in cohorts (healthy user effect); no RCTs yet.

Emphasizes N=1 individualized approach considering personal risks (e.g., prostate/heart disease).

Key Points and Decisions

**Low Endogenous Testosterone**: Strongly linked to higher mortality (all-cause, CV, cancer); associated with frailty, metabolic issues.

**Castration/Eunuch Data**: Suggests lifelong low T may extend life, but not directly comparable to adult TRT.

**TRT Evidence**: Cohort studies show mortality reduction with normalized levels (esp. long-term), but short-term CV risks possible; no definitive RCTs.

**No Firm Decisions**: Informational only; no endorsements for/against TRT; highlights need for RCTs to resolve controversy.

Next Steps

**Research**: Await randomized controlled trials (RCTs) for definitive TRT mortality data.

**Individuals**: Check testosterone/health markers regularly (yearly+); consult physicians for personalized risks/benefits; prioritize resistance training, healthy lifestyle.

**Audience**: Seek professional medical advice; follow show on YouTube, Spotify, Apple Podcasts, social media, goonpro.com.